Document Detail


A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
MedLine Citation:
PMID:  20932223     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This prospective, observational study investigated the haematological response to darbepoetin alfa (DA) administered every three weeks for the treatment of anaemia. Response was also assessed according to baseline characteristics including iron, folate and vitamin B12 status.
RESEARCH DESIGN AND METHODS: Anaemic adult patients with malignant non-myeloid cancer, starting or having already undergone chemotherapy received DA on day of inclusionand were followed up for up to 24 weeks. Concentration of haemoglobin (Hb), as well as iron, vitamin B12 and folate status where available, were recorded at inclusion, after a treatment period of 9 weeks and up to a maximum of 24 weeks or cessation of DA treatment, whichever was sooner.
MAIN OUTCOME MEASURES: The main outcome measure assessed in this study was the percentage of patients reaching a Hb concentration of at least 11 g/dL at least once at any time during the study.
RESULTS: A total of 2912 patients were included. The mean Hb concentration increased from 10.0 g/dL at inclusion to 11.4 g/dL at 9 weeks and 11.8 g/dL at 24 weeks. In 74.6% of patients the target Hb level of 11.0 g/dL or above was reached. After initiation of DA treatment, 9.5% of patients required a blood transfusion by week 9, and 5.6% thereafter. Vitamin B12 and folate status were unknown for 80.3% of patients and the iron status for 73.2% of patients. Compared with patients who remained untreated for vitamin B12 or folate deficiency, a higher percentage of patients with vitamin status within normal limits achieved the target Hb concentration. However, achievement of target Hb level appeared not to be affected by iron status.
CONCLUSIONS: In this study, the mean Hb level increased in anaemic cancer patients treated with DA and the majority of patients achieved the target Hb level. In contrast to the recommendations of guidelines (EORTC) encouraging the measurement of iron and vitamin levels, the present study demonstrated that data were not routinely collected for these factors.
Authors:
I Ray-Coquard; P Laplaige; N Vey; B Asselain; M Urbieta
Related Documents :
14740503 - Anemia as a risk factor for ischemic heart disease.
15153713 - Hematologic manifestation of childhood celiac disease.
1633723 - Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthr...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-10-11
Journal Detail:
Title:  Current medical research and opinion     Volume:  26     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-20     Completed Date:  2011-03-22     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2653-60     Citation Subset:  IM    
Affiliation:
Centre Leon Bérard, 28 rue Laennec, 69008, Lyon, France. RAY@lyon.fnclcc.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / drug therapy*,  etiology
Antineoplastic Agents / adverse effects
Cohort Studies
Dietary Supplements
Erythropoietin / administration & dosage,  analogs & derivatives*,  therapeutic use
Female
Folic Acid / blood
France
Hematinics / administration & dosage,  therapeutic use*
Humans
Iron / blood
Male
Middle Aged
Neoplasm Metastasis / drug therapy*
Neoplasms / complications,  drug therapy
Prospective Studies
Vitamin B 12 / blood
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hematinics; 11096-26-7/Erythropoietin; 15UQ94PT4P/darbepoetin alfa; 59-30-3/Folic Acid; 68-19-9/Vitamin B 12; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term safety of duloxetine during open-label compassionate use treatment of patients who complet...
Next Document:  Oral salmon calcitonin--pharmacology in osteoporosis.